Medpace reports Q3 2026 earnings beat, launches $1 billion buyback and updates 2026 guidance
+1 new source since this summary was written
Medpace Holdings announced its third‑quarter 2026 results, posting revenue of $716.0 million, up 8.5% year‑on‑year, and GAAP net income of $137.5 million, or $4.84 per diluted share. The company beat consensus EPS estimates by $0.40 and exceeded revenue forecasts by $2.3 million. It also launched a $1 billion stock repurchase program and reaffirmed full‑year revenue guidance of $2.835 billion‑$2.855 billion while raising its FY 2026 diluted GAAP EPS outlook.
Why it matters
The earnings beat and buyback signal strong cash generation, which may support the stock price despite the slightly lower revenue guidance. The updated EPS guidance, higher than consensus, could influence analyst forecasts and investor expectations for FY 2026.
Key facts
- 1Q3 2026 revenue was $716.0 million, up 8.5% YoY. stocktitan.net
- 2GAAP net income was $137.5 million, or $4.84 per diluted share. stocktitan.net
- 3EPS of $4.84 beat consensus estimates by $0.40. investing.com
- 4Revenue topped estimates by $2.3 million. finance.yahoo.com
- 5The board approved a $1 billion stock repurchase authorization. tradingview.com
- 6Full‑year 2026 revenue guidance reaffirmed at $2.835 billion‑$2.855 billion. tradingview.com
Open questions
- Material 6 reports FY 2026 diluted GAAP EPS guidance raised to $18.15, while material 9 gives a range of $17.97‑$18.32.
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.